HGF/c-Met Inhibition as Adjuvant Therapy Improves Outcomes in an Orthotopic Mouse Model of Pancreatic Cancer

HGF/c-Met Inhibition as Adjuvant Therapy Improves Outcomes in an Orthotopic Mouse Model of Pancreatic Cancer

Background: Inhibition of hepatocyte growth factor (HGF)/c-MET pathway, a major mediator of pancreatic stellate cell (PSC)−PC cell interactions, retards local and distant cancer progression. This study examines the use of this treatment in preventing PC progression after resection. We further invest...

Full description

Bibliographic Details
Main Authors: Tony C. Y. Pang, Zhihong Xu, Alpha Raj Mekapogu, Srinivasa Pothula, Therese Becker, Susan Corley, Marc R. Wilkins, David Goldstein, Romano Pirola, Jeremy Wilson, Minoti Apte
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
pancreatic cancer
metastasis
circulating rare cells
circulating pancreatic stellate cells
circulating tumour cells
circulating stromal cells
Online Access:https://www.mdpi.com/2072-6694/13/11/2763

Internet

https://www.mdpi.com/2072-6694/13/11/2763

Similar Items